All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Business Development & Partnerships

GSK, Jackson Laboratory partner on five-year neurodegenerative disease research collaboration targeting Alzheimer's
Research collaboration, neurological, stem cell research, drug discovery, R&D - Read more

Novartis, Unnatural Products partner on cardiovascular macrocyclic peptides, $100M upfront, $1.7B milestones
Research collaboration, cardiovascular, macrocyclic peptides, milestone payments - Read more

Rasayana Therapeutics, Theriva Biologics license gastrointestinal candidate SYN-020 in $36M deal
Licensing deal, gastrointestinal, small molecule, milestone payments - Read more

Evogene, Queensland University of Technology collaborate on AI-driven small molecule discovery for chemotherapy-resistant cancer
Research collaboration, oncology, AI/ML, small molecule, drug discovery - Read more

Merck & Co., Mayo Clinic partner on AI drug discovery using multimodal patient data platform
Research collaboration, AI/ML, autoimmune, drug discovery - Read more

Recipharm, Scinai Immunotherapeutics partner on Israel API plant sale and CDMO collaboration
Manufacturing agreement, CDMO partnership, small molecule, API manufacturing - Read more

THE GOOD
Clinical Trials

Eli Lilly's Zepbound (tirzepatide) plus Taltz combination shows Ph3 efficacy in moderate-to-severe plaque psoriasis
Small molecule, autoimmune, GLP-1/GIP agonist, psoriasis, combination therapy, IL-17A inhibitor - Read more

Novartis' Rhapsido (remibrutinib) hits Ph3 goals for chronic inducible urticaria, BTK inhibitor targets label expansion
Small molecule, autoimmune, BTK inhibitor, chronic urticaria, remibrutinib - Read more

NeuroSense Therapeutics' PrimeC shows 65% death risk reduction in amyotrophic lateral sclerosis Ph2 trial
Small molecule, neurological, ALS, combination therapy, neuroprotection - Read more

Moleculin Biotech reports 40% preliminary complete remission rate for Annamycin in Ph2/3 acute myeloid leukemia trial
Small molecule, cancer, anthracycline, acute myeloid leukemia, combination therapy - Read more

NeuExcell Therapeutics reports positive Ph1 results for gene therapy targeting recurrent malignant glioma brain cancer
Gene therapy, cancer, malignant glioma, brain cancer, regenerative medicine - Read more [Paywall]

PRESENTED BY FACET LIFE SCIENCES
Facet Life Sciences Makes Emerging Biotech Approvable

The pathway to FDA can be difficult to navigate when precedent is limited, and frameworks are thin.

Facet specializes in helping emerging biotech teams understand what your program must demonstrate, how regulators are likely to evaluate the evidence, and what constitutes a viable, and ultimately, approvable, path forward.

It’s a regulatory strategy that starts where it should: with your science and your goals. Not the other way around.

Book a free 30-minute intro session with Facet → click here

✅ More Good News ✅

THE GOOD
Company Launches

Korsana Biosciences launches with $150M series A to advance next-generation anti-amyloid Alzheimer's antibody KRSA-028
Monoclonal antibody, neurological, strategic, major transaction - Read more

THE GOOD
Fundraises

EIR Biopharma targets $17M IPO, preclinical eye disease drug development
Ophthalmology, preclinical, small molecule, rare disease - Read more

Starget Pharma raises $18M Series A, developing peptide radioligand therapies for cancer
Radiopharmaceutical, oncology, theranostic, AI-driven, clinical-stage - Read more

Pharmacelera raises €6M ($7.1M) funding, quantum mechanics AI for drug discovery platform
AI/ML platform, drug discovery, platform technology, quantum mechanics, computational - Read more

Eupraxia Pharmaceuticals announces proposed public offering for EP-104GI clinical development
Clinical-stage, platform technology, gastrointestinal, controlled drug delivery - Read more

THE GOOD
Investments

J&J to build $1B cell therapy plant in Pennsylvania, creating 500 jobs as part of their $55B US investment plan
Cell therapy, oncology, strategic, major transaction - Read more

THE GOOD
Mergers & Acquisitions

Danaher buys patient monitoring specialist Masimo in $9.9B deal to strengthen diagnostics portfolio
Medical devices, patient monitoring, strategic, major transaction - Read more

Sensei Biotherapeutics merges with Faeth Therapeutics, securing $200M funding to advance phase 2 cancer drug PIKTOR
Small molecule, oncology, strategic, major transaction - Read more

Axol Bioscience acquires Newcells Biotech ophthalmology unit to expand iPSC-derived retinal models portfolio
Cell therapy, ophthalmology, strategic, major transaction - Read more

THE GOOD
Politics & Policy

NIH Director Jay Bhattacharya named acting CDC chief following Jim O'Neill's departure this week
Vaccine, infectious disease, regulatory, operational - Read more

THE GOOD
Product Launches

Within3 introduces Dataverse ecosystem to expand real-world data coverage for pharma launch intelligence platform
Data analytics platform, strategic, operational, competitive - Read more

THE GOOD
Regulatory

Senate HELP Committee chair Cassidy proposes FDA reforms targeting clinical trials, rare diseases, biosimilars regulation
Cell and gene therapy, rare disease, regulatory, strategic - Read more

FDA accepts Moderna's amended mRNA-1010 influenza vaccine application for review with August decision target
Vaccine, infectious disease, mRNA vaccine, influenza, elderly population - Read more

PRESENTED BY YOU?
Get the attention of 2500+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

THE BAD
Lawsuits

Court rejects Moderna's obviousness and derivation defenses in Arbutus Biopharma mRNA vaccine patent lawsuit
mRNA vaccine, infectious disease, operational, strategic - Read more

THE UGLY
No Ugly News Today!

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here